Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
case report on the co presentation of pituitary abscess and poems like syndrome
Original title: “A case report on the co-presentation of pituitary abscess and POEMS-like syndrome.”
hiv negative kshv hhv8 associated multicentric castleman disease with concurrent kaposi sarcoma and poems like manifestations
Original title: “HIV-negative KSHV/HHV8-associated multicentric Castleman disease with concurrent Kaposi sarcoma and POEMS-like manifestations.”
academic bcma car t ari0002h achieves mrd negative remission with sbcma biomarker response in relapsed poems syndrome after double asct
Original title: “Academic BCMA CAR-T (ARI0002h) achieves MRD-negative remission with sBCMA biomarker response in relapsed POEMS syndrome after double ASCT.”
100% complete response (“CR”) rate among all 15 CAR-T-naïve efficacy evaluable patients treated with TPST-2003 dual-targeting CD19/BCMA CAR-T across two... 100% CR as measured by normalization of serum vascular endothelial growth factor levels (“CRVEGF“) rate among all five efficacy evaluable patients in POEMS-1 trial evaluating TPST-2003 in the rare disease, POEMS syndrome ... Results support clinical benefit of parallel-structure dual-targeting CAR architecture in patients with rrMM, including in patients with extramedullary disease (“EMD”) Median progression free survival of 23.1 months, including in patients with EMD, if replicated in registrational trial, would position TPST-2003 as potentially class-leading therapy for rrMM TPST-2003 is being developed in China by Tempest’s partner, Novatim Immune Therapeutics (“Novatim”). Under its agreement with Novatim, Tempest has the exclusive right to develop TPST-2003 outside of China, India, Turkey, and Russia. ... REDEEM-1 (Study nos. CTR20233309/NCT06223646) is a Phase 1/2a clinical trial evaluating TPST-2003 in patients with relapsed/refractory multiple myeloma, including patients with high-risk cytogenetics and patients with extramedullary disease. Xiaojing Yan), and The Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College (Dr. Dehui Zou). ... POEMS-1 is a Phase 1 clinical trial (Study nos. CTR20242409/NCT06518876) evaluating TPST-2003 in patients with POEMS, a rare blood disorder caused by abnormal plasma cells. NCT04714827) is evaluating TPST-2003 in patients with relapsed/refractory multiple myeloma, including patients with high-risk cytogenetics and patients with extramedullary disease. The IIT is sponsored and being conducted by Tempest’s partner, Novatim, with a total of two clinical sites registered in China: Shanghai Fourth People’s Hospital (Dr. Weijun Fu; lead site) and Shanxi Provincial Cancer Hospital (Dr. Liping Su). ... Tempest Therapeutics is a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy product candidates to treat cancer.
Original title: “Tempest Presents Clinical Update at ISCT 2026 Annual Meeting”
morphological characteristics of the renal lesion in tafro syndrome and poems syndrome a retrospective and multicenter study
Original title: “Morphological characteristics of the renal lesion in TAFRO syndrome and POEMS syndrome: a retrospective and multicenter study.”
prognostic value of the neutrophil to lymphocyte ratio in poems syndrome
Original title: “Prognostic value of the neutrophil-to-lymphocyte ratio in POEMS syndrome.”